FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1989544135> ?p ?o ?g. }

• W1989544135 endingPage "21284" @default.
• W1989544135 startingPage "21279" @default.
• W1989544135 abstract "The cystic fibrosis transmembrane conductance regulator (CFTR) contains multiple membrane spanning sequences that form a Cl− channel pore and cytosolic domains that control the opening and closing of the channel. The fourth intracellular loop (ICL4), which connects the tenth and eleventh transmembrane spans, has a primary sequence that is highly conserved across species, is the site of a preserved sequence motif in the ABC transporter family, and contains a relatively large number of missense mutations associated with cystic fibrosis (CF). To investigate the role of ICL4 in CFTR function and to learn how CF mutations in this region disrupt function, we studied several CF-associated ICL4 mutants. We found that most ICL4 mutants disrupted the biosynthetic processing of CFTR, although not as severely as the most common ΔF508 mutation. The mutations had no discernible effect on the channel's pore properties; but some altered gating behavior, the response to increasing concentrations of ATP, and stimulation in response to pyrophosphate. These effects on activity were similar to those observed with mutations in the nucleotide-binding domains, suggesting that ICL4 might help couple activity of the nucleotide-binding domains to gating of the Cl− channel pore. The data also explain how these mutations cause a loss of CFTR function and suggest that some patients with mutations in ICL4 may have a milder clinical phenotype because they retain partial activity of CFTR at the cell membrane. The cystic fibrosis transmembrane conductance regulator (CFTR) contains multiple membrane spanning sequences that form a Cl− channel pore and cytosolic domains that control the opening and closing of the channel. The fourth intracellular loop (ICL4), which connects the tenth and eleventh transmembrane spans, has a primary sequence that is highly conserved across species, is the site of a preserved sequence motif in the ABC transporter family, and contains a relatively large number of missense mutations associated with cystic fibrosis (CF). To investigate the role of ICL4 in CFTR function and to learn how CF mutations in this region disrupt function, we studied several CF-associated ICL4 mutants. We found that most ICL4 mutants disrupted the biosynthetic processing of CFTR, although not as severely as the most common ΔF508 mutation. The mutations had no discernible effect on the channel's pore properties; but some altered gating behavior, the response to increasing concentrations of ATP, and stimulation in response to pyrophosphate. These effects on activity were similar to those observed with mutations in the nucleotide-binding domains, suggesting that ICL4 might help couple activity of the nucleotide-binding domains to gating of the Cl− channel pore. The data also explain how these mutations cause a loss of CFTR function and suggest that some patients with mutations in ICL4 may have a milder clinical phenotype because they retain partial activity of CFTR at the cell membrane. The cystic fibrosis transmembrane conductance regulator (CFTR) 1The abbreviations used are: CFTRcystic fibrosis transmembrane conductance regulatorCFcystic fibrosisICLintracellular loopNBDnucleotide-binding domainMSDmembrane-spanning domainMtransmembrane domainABC transporterATP binding cassette transporterPKAcatalytic subunit of cAMP-dependent protein kinasePPipyrophosphateCPT-cAMP8-(4-chlorophenylthio)-adenosine 3′:5′-cyclic monophosphate sodium saltPoopen state probabilityI-V relationshipcurrent-voltage relationshipTESN-tris[hydroxymethyl]methyl-2-aminoethanesulfonic acid. is a phosphorylation-regulated, ATP-dependent Cl− channel (for review, see Refs. 1Welsh M.J. Anderson M.P. Rich D.P. Berger H.A. Denning G.M. Ostedgaard L.S. Sheppard D.N. Cheng S.H. Gregory R.J. Smith A.E. Neuron. 1992; 8: 821-829Google Scholar and 2Riordan J.R. Annu. Rev. Physiol. 1993; 55: 609-630Google Scholar) that belongs to the ATP Binding Cassette (ABC) transporter family (3Hyde S.C. Emsley P. Hartshorn M.J. Mimmack M.M. Gileadi U. Pearce S.R. Gallagher M.P. Gill D.R. Hubbard R.E. Higgins C.F. Nature. 1990; 346: 362-365Google Scholar). Like other members of this family, CFTR has two nucleotide-binding domains (NBD1 and NBD2) and two membrane-spanning domains (MSD1 and MSD2). In CFTR, each MSD is composed of six putative transmembrane segments (M1-6 and M7-12, respectively) and their connecting intracellular and extracellular loops. CFTR also contains a unique R domain which is involved in phosphorylation-dependent regulation of Cl− channel activity. cystic fibrosis transmembrane conductance regulator cystic fibrosis intracellular loop nucleotide-binding domain membrane-spanning domain transmembrane domain ATP binding cassette transporter catalytic subunit of cAMP-dependent protein kinase pyrophosphate 8-(4-chlorophenylthio)-adenosine 3′:5′-cyclic monophosphate sodium salt open state probability current-voltage relationship N-tris[hydroxymethyl]methyl-2-aminoethanesulfonic acid. Mutations in the gene encoding CFTR cause the common genetic disease cystic fibrosis (CF) (4Welsh M.J. Tsui L.-C. Boat T.F. Beaudet A.L. Scriver C.R. Beaudet A.L. Sly W.S. Valle D. The Metabolic and Molecular Basis of Inherited Disease. McGraw-Hill Inc., New York1995: 3799Google Scholar). Although CF-associated missense mutations have been discovered throughout the coding region of the CFTR gene (5Tsui L.C. Hum. Mutat. 1992; 1: 197-203Google Scholar), certain regions appear to have a relatively high frequency of missense mutations; for example, M1, M6, and specific regions of NBD1 are the sites of many missense mutations. The study of CF-associated missense mutations in these regions has helped elucidate the function of CFTR and has shown how the mutations disrupt function in CF. Studies of mutations in M1 and M6 have shown that these regions contribute to the Cl− conducting pore (6Sheppard D.N. Rich D.P. Ostedgaard L.S. Gregory R.J. Smith A.E. Welsh M.J. Nature. 1993; 362: 160-164Google Scholar, 7Tabcharani J.A. Rommens J.M. Hou Y.-X. Chang X.-B. Tsui L.-C. Riordan J.R. Hanrahan J.W. Nature. 1993; 366: 79-82Google Scholar), and studies of mutations in NBD1 have helped investigators understand ATP-dependent gating and biosynthesis of CFTR (8Anderson M.P. Welsh M.J. Science. 1992; 257: 1701-1704Google Scholar, 9Denning G.M. Anderson M.P. Amara J.F. Marshall J. Smith A.E. Welsh M.J. Nature. 1992; 358: 761-764Google Scholar, 10Sheppard D.N. Ostedgaard L.S. Winter M.C. Welsh M.J. EMBO J. 1995; 14: 876-883Google Scholar, 11Drumm M.L. Wilkinson D.J. Smit L.S. Worrell R.T. Strong T.V. Frizzell R.A. Dawson D.C. Collins F.S. Science. 1991; 254: 1797-1799Google Scholar, 12Dalemans W. Barbry P. Champigny G. Jallat S. Dott K. Dreyer D. Crystal R.G. Pavirani A. Lecocq J.P. Lazdunski M. Nature. 1991; 354: 526-528Google Scholar, 13Champigny G. Imler J.L. Puchelle E. Dalemans W. Gribkoff V. Hinnrasky J. Dott K. Barbry P. Pavirani A. Lazdunski M. EMBO J. 1995; 14: 2417-2423Google Scholar, 14Yang Y. Devor D.C. Engelhardt J.F. Ernst S.A. Strong T.V. Collins F.S. Cohn J.A. Frizzell R.A. Wilson J.M. Hum. Mol. Genet. 1993; 2: 1253-1261Google Scholar). Examination of the distribution of CF-associated missense mutations shows that the fourth intracellular loop (ICL4) which lies between M10 and M11 is another region that contains many missense mutations: at least 19 CF-associated missense mutations have been discovered in this loop (Fig. 1) (15Férec C. Audrézet M.P. Mercier B. Guillermit H. Moullier P. Quéré I. Verlingue C. Nat. Genet. 1992; 1: 188-191Google Scholar, 16Fanen P. Ghanem N. Vidaud M. Besmond C. Martin J. Costyes B. Plassa F. Goossens M. Genomics. 1992; 13: 770-776Google Scholar, 17Mercier B. Lissens W. Novelli G. Kalaydjieva L. DeArce M. Kapranov N. Canki-Klain N. Lenoir G. Chauveau P. Lenaerts C. Rault S. Cashman S. Sanguiolo F. Audrézet M.P. Dallapiccola B. Guillermit H. Bonduelle M. Liebaers I. Quéré I. Verlingue C. Ferec C. Genomics. 1993; 16: 296-297Google Scholar, 18Ghanem N. Costes B. Girodon E. Martin J. Fanen P. Goossens M. Genomics. 1994; 21: 434-436Google Scholar, 19Savov A. Mercier B. Kalaydjieva L. Férec C. Hum. Mol. Genet. 1994; 3: 57-60Google Scholar, 20Bozon D. Zielenski J. Rininsland F. Tsui L.-C. Hum. Mutat. 1994; 3: 330-332Google Scholar). 2R1066S (C. Férec, I. Quere, C. Verlingue, O. Raguenes, M.-P. Audrezet, and B. Mercier, personal communication), F1074L (T. Casals, M. D. Ramos, J. Giménez, V. Nunes, and X. Estivill, personal communication), K1060T (T. Casals, M. Chillón, V. Nunes, J. Giménez, M. D. Ramos, and X. Estivill, personal communication), L1065R (T. Casals, M. D. Ramos, J. Giménez, V. Nunes, and X. Estivill, personal communication), T1086I (T. Bienvenu, S. Bousquet, C. Herbulot, C. Beldjord, and J. C. Kaplan, personal communication), and R1070W (M. Macek, S. Sedriks, S. Kiesewetter, and G. R. Cutting, personal communication). Interestingly, one residue within ICL4, R1066, has been reported to have four separate CF-associated mutations: R1066C, R1066H, R1066L, and R1066S. Inspection of CFTR sequences from various species including human, rat, mouse, bovine, ovine, frog, and shark shows substantial sequence conservation throughout the MSDs, particularly within the intracellular loops. Evolutionary maintenance of these residues suggests that they have an important function. Additional support for an important function came from a recent study by Manavalan et al. (21Manavalan P. Smith A.E. McPherson J.M. J. Protein Chem. 1993; 12: 279-290Google Scholar) who compared the length, sequence, and predicted secondary structure of the intra- and extracellular loops of the MSDs of various ABC transporters. Their study showed that the length of the intracellular loops was conserved, and they uncovered a consensus sequence in ICL4 (Fig. 1). This consensus sequence encompasses the cluster of CF-causing mutations in ICL4. Based on these observations, we hypothesized that ICL4 may play an important role in the structure and function of CFTR. To test this hypothesis and to learn how CF-associated mutations in ICL4 disrupt function, we constructed several of the CF-associated mutants in this region by site-directed mutagenesis, expressed them in heterologous cells, and studied their processing and function. CFTR mutants were constructed in the vaccinia virus expression plasmid pTM-CFTR4 (22Cheng S.H. Gregory R.J. Marshall J. Paul S. Souza D.W. White G.A. O'Riordan C.R. Smith A.E. Cell. 1990; 63: 827-834Google Scholar) by the method of Kunkel (23Kunkel T.A. Proc. Natl. Acad. Sci. U. S. A. 1985; 82: 488-492Google Scholar). Mutations were verified by restriction enzyme analysis, DNA sequencing around the site of mutation, and in vitro expression. Wild-type and mutant CFTR were transiently expressed in HeLa cells using the vaccinia virus/T7 bacteriophage hybrid expression system as described previously (8Anderson M.P. Welsh M.J. Science. 1992; 257: 1701-1704Google Scholar). Cells were studied 14 to 24 h after transfection. We followed a protocol described previously (24Denning G.M. Ostedgaard L.S. Welsh M.J. J. Cell Biol. 1992; 118: 551-559Google Scholar). Briefly, soluble lysates of HeLa cells expressing the various constructs were immunoprecipitated with antibody M1-4 (9Denning G.M. Anderson M.P. Amara J.F. Marshall J. Smith A.E. Welsh M.J. Nature. 1992; 358: 761-764Google Scholar), which recognizes the C terminus of CFTR, phosphorylated with [γ-32P]ATP and the catalytic subunit of PKA, and separated on a 6% SDS-polyacrylamide gel. Radioactivity was quantitated using a radioanalytical imaging system (AMBIS, San Diego, CA). Methods for excised, inside-out, and whole cell patch-clamp recording have been described previously (10Sheppard D.N. Ostedgaard L.S. Winter M.C. Welsh M.J. EMBO J. 1995; 14: 876-883Google Scholar, 25Hamill O.P. Marty A. Neher E. Sakmann B. Sigworth F.J. Pflugers Arch. 1981; 391: 85-100Google Scholar, 26Carson M.R. Welsh M.J. Am. J. Physiol. 1993; 265: L27-L32Google Scholar). Voltages are referenced to the extracellular side of the membrane. Whole cell and excised macropatch data were collected at potentials of +20 and −40 mV, respectively; single channel data were recorded at a holding potential of −80 mV for kinetic analysis. Experiments were conducted at 34-36°C. Liquid junction potentials and potentials at the tip of the patch-pipette were measured and current-voltage (I-V) relationships corrected for the corresponding offset. In whole cell studies, CFTR Cl− channels were activated with cAMP agonists (10 µ forskolin, 100 µ 3-isobutyl-1-methylxanthine, and 500 µ 8-(4-chlorophenylthio)-adenosine 3′:5′-cyclic monophosphate sodium salt (CPT-cAMP). In excised, inside-out patches of membrane, CFTR was activated with the catalytic subunit of cAMP-dependent protein kinase (PKA, Promega Corp., Madison, WI) and 1 m ATP (ATP, disodium salt, Sigma). For excised inside-out patch experiments, the pipette (extracellular) solution contained (in m): 140 N-methyl—glucamine, 100 aspartic acid, 35.5 HCl, 5 CaCl2, 2 MgCl2, 10 TES, pH 7.3, with 1 NaOH (final Cl− concentration was 49.5 m). The bath (intracellular) solution contained (in m): 140 N-methyl—glucamine, 135.5 HCl, 3 MgCl2, 10 TES, 4 Cs(OH)2/1 EGTA, pH 7.3, with 1 HCl (free Ca2+ concentration was < 10−8 and final Cl− concentration was approximately 146 m). For whole cell experiments, the pipette (intracellular) solution contained (in m): 120 N-methyl—glucamine, 85 m aspartic acid, 3 MgCl2, 10 TES, 4 Cs(OH)2, 1 EGTA, 1 m Na2ATP, pH 7.3, with 1 HCl (free Ca2+ concentration was <10−8 and final Cl− concentration was approximately 41 m). The bath (extracellular) solution contained (in m): 140 NaCl, 10 TES, 1.2 MgSO4, 1.2 CaCl2, and 30 m dextrose, pH 7.3, with 1 NaOH (final Cl− concentration was approximately 142.4 m). For anion selectivity experiments using excised inside-out patches, the pipette (extracellular) solution contained (in m): 110 N-methyl—glucamine, 100 aspartic acid, 30 NaCl, 10 TES, 5 CaCl2, 2 MgCl2, pH 7.3, with 1 HCl. The bath (intracellular) solution contained (in m): 140 of NaCl, NaBr, or NaI, 10 TES, 3 MgCl2, 4 Cs(OH)2/1 EGTA, pH 7.3, with 1 NaOH. Twenty to 40 1-s ramps of voltage from −100 to +60 mV were averaged to obtain the I-V relationship for calculation of permeability and conductance ratios in excised macropatches. Permeability ratios, PX/PCl, where X is Br− or I−, were calculated from reversal potential (Erev) measurements using the Goldman-Hodgkin-Katz equation, as described previously (27Anderson M.P. Gregory R.J. Thompson S. Souza D.W. Paul S. Mulligan R.C. Smith A.E. Welsh M.J. Science. 1991; 253: 202-205Google Scholar). Chord conductance was measured as the slope between Erev and Erev minus 25 mV. Conductance ratios, GX/GCl, where X is Br− or I−, are the ratio of chord conductance of Br− or I− relative to that of Cl−. Single-channel current amplitudes were determined from distributions of current in amplitude histograms. The fit of linear least squares regression lines to single-channel I-V relationships was used to determine single-channel conductance at negative voltages, where I-V relationships were linear. For whole cell and excised macropatch data, replayed records were filtered at 1 kHz using a variable 8-pole Bessel filter (Frequency Devices Inc., Haverhill, MA) and digitized at 2 kHz. For single channel analysis, replayed data were filtered at 1 kHz using a variable 8-pole Bessel filter, digitized at 5 kHz, and digitally filtered at 500 Hz. Event lists for single channel analysis were created using a half-height transition protocol; transitions less than 1 ms in duration were excluded from analysis. To derive open and closed time constants, single channel open and closed time histograms were plotted with a logarithmic abscissa with 10 bins/decade and were fit with both one and two component exponential functions using the maximum likelihood method, with a lower fitting limit of 2.5 ms. To determine if the two component function fit statistically better than a one component fit, the log likelihood ratio test was used and considered significant at a value of 2.0 or greater. Burst analysis was performed as described previously using the pClamp 6.0 software package (28Carson M.R. Travis S.M. Welsh M.J. J. Biol. Chem. 1995; 270: 1711-1717Google Scholar). We used a tc (the time which delineates interburst from intraburst closures) of 20 ms as derived from single channel closed time histograms. A tc of 20 ms was found suitable for all ICL4 mutants as well as wild-type CFTR. Regions of data from patches containing greater than one active channel with no superimposed openings were used for burst duration analysis as described previously (28Carson M.R. Travis S.M. Welsh M.J. J. Biol. Chem. 1995; 270: 1711-1717Google Scholar). Results are presented as means ± S.E. for n observations. Statistical significance was determined using a log likelihood ratio test or an unpaired Student's t test where appropriate. p values <0.05 were considered statistically significant. Many CF-associated mutations cause a loss of CFTR Cl− channel function by disrupting biosynthetic processing such that the mutant protein is not delivered to the cell membrane (see Ref. 29Welsh M.J. Smith A.E. Cell. 1993; 73: 1251-1254Google Scholar, for a review). Processing of CFTR can be assessed by examining its glycosylation state(s). Electrophoresis of wild-type CFTR resolves two bands: a broad, slowly migrating band (band C) that represents mature protein, and a more rapidly migrating band (band B) that represents immature protein (Fig. 2). Band C is endoglycosidase H resistant, consistent with protein that has migrated through the Golgi complex (22Cheng S.H. Gregory R.J. Marshall J. Paul S. Souza D.W. White G.A. O'Riordan C.R. Smith A.E. Cell. 1990; 63: 827-834Google Scholar). Band B is endoglycosidase H sensitive, consistent with core glycosylation and retention in the endoplasmic reticulum. CFTR with the most common CF-associated mutation, ΔF508, produces a protein which is retained in the endoplasmic reticulum and is only core glycosylated (band B) (Fig. 2A). Fig. 2A shows that all the ICL4 mutations studied produced protein. However, the relative amount of the mature band C form of CFTR varied widely. For example, levels of mature F1052V were similar to wild-type, whereas L1065P, R1070Q, and H1085R were similar to ΔF508 in that they produced little mature protein (Fig. 2, A and B). The other ICL4 mutants expressed intermediate amounts of mature protein. Although in some places it appears that two bands may be present in the area marked as band C, this was not a consistent finding. In Fig. 2 the processing of ΔF508 and the milder CF-associated mutant, P574H (10Sheppard D.N. Ostedgaard L.S. Winter M.C. Welsh M.J. EMBO J. 1995; 14: 876-883Google Scholar), are provided for reference. To evaluate the effect of ICL4 mutations on Cl− channel activity, we selected the mutants R1066C, R1066H, R1066L, A1067T, and F1052V for study. The three mutants at residue Arg-1066 and the one at Ala-1067 were of interest because they lie within the center of the cluster of CF causing mutations, because they are encompassed by the ABC transporter consensus sequence, and because they show different levels of defective processing. We also selected F1052V, which lies outside the cluster of mutations and the ABC transporter consensus sequence, because we thought it would likely have a functional defect since it is associated with CF yet is processed like wild-type protein. We initially used the whole cell patch-clamp technique to test if mutants form regulated Cl− channels. We found that cells expressing all of the ICL4 mutants (F1052V, R1066C, R1066H, R1066L, and A1067T) generated cAMP-stimulated Cl− selective currents that showed time- and voltage-independent behavior identical to that of wild-type CFTR (data not shown). These data indicate that CFTR variants bearing mutations in ICL4 are able to form regulated Cl− channels with several properties similar to those of wild-type protein. However, the fact that each of the ICL4 mutants is associated with CF suggested that in addition to defective processing they may possess functional characteristics different from that of the wild-type protein. A region of increased hydrophobicity lies in the middle of ICL4 (21Manavalan P. Smith A.E. McPherson J.M. J. Protein Chem. 1993; 12: 279-290Google Scholar) (Fig. 1). It is possible that such a region might be associated with the plasma membrane where it could contribute to the formation of the channel pore. An emerging theme in the construction of ion channels is that intra- and extracellular loops fold back into the plasma membrane and line the permeation pathway (30Jan L.Y. Jan Y.N. Nature. 1994; 371: 119-122Google Scholar, 31MacKinnon R. Neuron. 1995; 14: 889-892Google Scholar). Therefore, we asked whether the ICL4 mutations altered the conductive properties of the channel using excised, inside-out patches of membrane. Fig. 3 shows representative single-channel traces from the mutants. Mutations did not alter single-channel conductance: wild-type, 8.9 ± 0.3 pS; F1052V, 9.6 ± 0.2 pS; R1066C, 8.9 ± 0.4 pS; R1066H, 8.5 ± 0.7; R1066C, 8.6 ± 0.3; and A1067T, 9.2 ± 0.2 pS. Using excised patches of membrane, we also examined the relative anion permeability and conductivity sequence for 3 of the mutants. Table I shows that F1052V, R1066L, and A1067T did not alter the relative permeability or conductivity sequence for Cl−, Br−, or I−. These data suggest that the mutations in ICL4 did not alter the conductive properties of CFTR Cl− channels.TABLE IEffect of ICL4 mutations on anion selectivitynPx/PCLGx/GCLBr−Cl−I−Br−Cl−I−Wild-type31.29 ± 0.071.000.56 ± 0.131.18 ± 0.561.000.35 ± 0.06F1052V21.411.000.500.981.000.53R1066L41.36 ± 0.071.000.88 ± 0.111.15 ± 0.221.000.40 ± 0.11A1067T41.29 ± 0.151.000.66 ± 0.041.00 ± 0.101.000.43 ± 0.06 Open table in a new tab In agreement with our whole cell data, excised patch studies demonstrated that all of the mutants were both PKA- and ATP-dependent (data not shown). However, some of the ICL4 mutants had readily apparent alterations in gating. Fig. 3 shows single channel tracings selected to illustrate these differences. The most noticeable differences compared to wild-type were that the R1066C channels had longer closed times between bursts of activity. In addition, the Arg-1066 mutants and F1052V appeared to have bursts of activity with altered durations. The differences in gating were quantified in Fig. 4, Fig. 5. Interestingly, mutation of Arg-1066 to cysteine reduced open state probability (Po) (Fig. 3, Fig. 4A), yet when this same residue was mutated to histidine or leucine there was no effect on Po. The decrease in Po of R1066C was not due to a decrease in burst duration, but was instead due to an increased long closed time between bursts of activity (Fig. 3, Fig. 4, Fig. 5C). In contrast to the cysteine mutation, mutation of Arg-1066 to histidine did not significantly alter any of the kinetics and mutation to leucine produced a small decrease in burst duration and increase in fast closed time. Mutation of the adjacent residue Ala-1067 to threonine produced a different pattern; Po was decreased primarily because of a decrease in burst duration.Fig. 5Open and closed time constants for wild-type CFTR and ICL4 mutants. Time constants were plotted and fit as described under “Experimental Procedures.”τo refers to open time constant, τcf refers to fast closed time constant, and τcs refers to slow closed time constant. n = at least three for each, except n = 2 for τcs for R1066C. Asterisks indicate p < 0.05 relative to wild-type.View Large Image Figure ViewerDownload (PPT) These findings show that ICL4 mutations altered channel gating without affecting Cl− permeation. These effects are similar to the effect of mutations in the NBDs of CFTR (10Sheppard D.N. Ostedgaard L.S. Winter M.C. Welsh M.J. EMBO J. 1995; 14: 876-883Google Scholar, 28Carson M.R. Travis S.M. Welsh M.J. J. Biol. Chem. 1995; 270: 1711-1717Google Scholar, 32Carson M.R. Welsh M.J. Biophys. J. 1995; 69: 2443-2448Google Scholar), suggesting the possibility of a functional interaction between these CFTR domains. Therefore we speculated that ICL4 mutations might disrupt or modify some aspect of NBD-mediated gating; i.e. they might alter the interaction with ATP or they might affect the way the channel responds to agents whose effect is mediated through the NBDs. To test this hypothesis we first examined the effect of increasing concentrations of ATP on channel activity. We studied R1066L and A1067T because they showed altered gating (Fig. 4, Fig. 5); we did not study R1066C because it was difficult to study in excised, inside-out membrane patches, possibly because of its very low Po and poor processing. Fig. 6 shows that as the concentration of ATP increased, the Po of wild-type and mutant CFTR increased. R1066L had a response identical to that of wild-type CFTR. The maximum Po of A1067T was decreased, but the shape of the concentration Po curve mirrored that of wild-type. As we have previously reported (8Anderson M.P. Welsh M.J. Science. 1992; 257: 1701-1704Google Scholar), the shape of the curves did not fit simple Michaelis kinetics. This pattern of response for A1067T is similar to what we have found with the NBD mutants G551D, G1244E, and G1349D (8Anderson M.P. Welsh M.J. Science. 1992; 257: 1701-1704Google Scholar). The decrease in maximum Po without a change in the shape of the dose-response curve suggests that in A1067T ATP binding may be unaltered but that a step distal to binding may be affected. To investigate further a potential interaction between ICL4 and the NBDs, we examined the effect of PPi on several ICL4 mutants. Previous studies have shown that pyrophosphate (PPi) stimulates CFTR Cl− channels through an interaction with the NBDs (33Gunderson K.L. Kopito R.R. J. Biol. Chem. 1994; 269: 19349-19353Google Scholar, 34Carson M.R. Winter M.C. Travis S.M. Welsh M.J. J. Biol. Chem. 1995; 270: 20466-20472Google Scholar). PPi increases the Po of wild-type CFTR by prolonging the burst duration and by decreasing the interburst interval, effects which suggest that it interacts primarily with NBD2 (34Carson M.R. Winter M.C. Travis S.M. Welsh M.J. J. Biol. Chem. 1995; 270: 20466-20472Google Scholar). Fig. 7A shows that application of PPi to the cytosolic surface of an excised macropatch reversibly increased the activity of R1066L channels. However, Fig. 7B shows that the response of R1066L and F1052V to PPi was less than that of wild-type CFTR. This result suggested that ICL4 mutations may have altered an effect of PPi which is mediated through the NBDs, and perhaps specifically NBD2. To begin to isolate the effect of PPi to a specific NBD and to test further our hypothesis, we examined the response of several NBD mutants to PPi. We found that two NBD1 mutants, K464A and G551S, had a normal or increased response to PPi (Fig. 7C). In contrast, mutation of two analogous residues in NBD2, K1250M and G1349D, decreased the relative response to PPi. Each of these NBD1 and NBD2 mutations inhibit CFTR current to a similar extent. ICL4 of CFTR has a primary sequence that is highly preserved across species from elasmobranch to amphibian to mammals; it is the site of a conserved motif in the ABC transporter family, and it contains a relatively large number of residues that are sites of CF-associated missense mutations. Our data show that CF-associated mutations in ICL4 can disrupt the biosynthesis of CFTR and that some mutations altered gating of the channel. These considerations indicate that ICL4 plays an important role in determining the structure and function of CFTR. Previous studies have shown that CF-associated mutations can disrupt the processing of mutant CFTR so that it fails to escape from the endoplasmic reticulum and traffic to the plasma membrane. This is the primary defect in the most common CF mutation, ΔF508 (22Cheng S.H. Gregory R.J. Marshall J. Paul S. Souza D.W. White G.A. O'Riordan C.R. Smith A.E. Cell. 1990; 63: 827-834Google Scholar). Previous reports of defective processing have focused on CF-associated missense mutations in the NBDs (10Sheppard D.N. Ostedgaard L.S. Winter M.C. Welsh M.J. EMBO J. 1995; 14: 876-883Google Scholar, 13Champigny G. Imler J.L. Puchelle E. Dalemans W. Gribkoff V. Hinnrasky J. Dott K. Barbry P. Pavirani A. Lazdunski M. EMBO J. 1995; 14: 2417-2423Google Scholar, 22Cheng S.H. Gregory R.J. Marshall J. Paul S. Souza D.W. White G.A. O'Riordan C.R. Smith A.E. Cell. 1990; 63: 827-834Google Scholar, 35Gregory R.J. Rich D.P. Cheng S.H. Souza D.W. Paul S. Manavalan P. Anderson M.P. Welsh M.J. Smith A.E. Mol. Cell. Biol. 1991; 11: 3886-3893Google Scholar). The molecular basis for misprocessing of mutant CFTR is not well understood; presumably it results from altered folding and/or structure of the mutant protein with consequent recognition as abnormal and degradation by the cellular quality control system. Our results showing that ICL4 mutations disrupt processing suggest that ICL4 plays a critical structural role in the protein. ICL4 mutations could cause misprocessing because they disrupt the structure of ICL4 itself, or they could have an indirect effect by altering the structure of an associated part of the protein. More profound changes in ICL2 can also disrupt processing. Delaney et al. (36Delaney S.J. Rich D.P. Thomson S.A. Hargrave M.R. Lovelock P.K. Welsh M.J. Wainwright B.J. Nat. Genet. 1993; 4: 426-431Google Scholar) found that deletion of exon 5 (residues 163-193) disrupted processing and hence Cl− channel activity. Xie et al. (37Xie J. Drumm M.L. Ma J. Davis P.B. J. Biol. Chem. 1995; 270: 28084-28091Google Scholar) reported that deletion of 19 residues from ICL2 (residues E267 to M285) produced a similar effect. However, when that channel was incorporated into lipid bilayers it produced regulated Cl− channels. In addition, when Chang et al. (38Chang X-B. Hou Y-X. Jensen T.J. Riordan J.R. J. Biol. Chem. 1994; 269: 18572-18575Google Scholar) introduced a glycosylation site into ICL4 at Val-1056 they found that the amount of protein decreased. In addition to their effect on processing, ICL4 mutations altered channel function. However, we could discern no relationship between the effect on processing and the effect on function. For example, the mutant F1052V was processed normally but had dramatically altered function, whereas the R1066H mutation had a dramatic effect on processing but little discernible effect on function. Moreover, mutation of Arg-1066 to three different residues, histidine, leucine, and cysteine, each decreased processing to roughly similar extents, yet had different effects on function. Clearly the requirements for channel processing and function are different. This conclusion is consistent with observations on NBD mutations; for example, the ΔF508 mutation is severely misprocessed yet retains approximately one-third of its function; whereas the G551D mutation is processed correctly but has very little function (9Denning G.M. Anderson M.P. Amara J.F. Marshall J. Smith A.E. Welsh M.J. Nature. 1992; 358: 761-764Google Scholar, 12Dalemans W. Barbry P. Champigny G. Jallat S. Dott K. Dreyer D. Crystal R.G. Pavirani A. Lecocq J.P. Lazdunski M. Nature. 1991; 354: 526-528Google Scholar, 14Yang Y. Devor D.C. Engelhardt J.F. Ernst S.A. Strong T.V. Collins F.S. Cohn J.A. Frizzell R.A. Wilson J.M. Hum. Mol. Genet. 1993; 2: 1253-1261Google Scholar, 35Gregory R.J. Rich D.P. Cheng S.H. Souza D.W. Paul S. Manavalan P. Anderson M.P. Welsh M.J. Smith A.E. Mol. Cell. Biol. 1991; 11: 3886-3893Google Scholar, 39Smit L.S. Wilkinson D.J. Mansoura M.K. Collins F.S. Dawson D.C. Proc. Natl. Acad. Sci. U. S. A. 1993; 90: 9963-9967Google Scholar). How might ICL4 participate in the Cl− channel function of CFTR? Our whole cell and excised patch data revealed no alteration of conductive properties, suggesting that ICL4 does not contribute directly to the conduction pore. Instead, ICL4 mutations altered the gating behavior. Because NBD mutations also alter gating, the data suggested the possibility of an interaction between ICL4 and the NBDs. The fact that ICL4 and NBD2 mutants reduced the response to PPi and the finding that G1349D and A1067T altered the effect of increasing concentrations of ATP in a similar way further suggest some interaction between ICL4 and the NBDs, particularly NBD2. In CFTR, some mechanism must exist for interaction between the NBDs, which control channel gating, and the MSDs which form the channel pore. There is evidence for such an interaction in other ABC transporters. In P-glycoprotein, transported substrate interacts with the MSDs and stimulates ATPase activity by the NBDs. Conversely, ATP hydrolysis by the NBDs stimulates drug efflux (40Sarkadi B. Price E.M. Boucher R.C. Germann U.A. Scarborough G.A. J. Biol. Chem. 1992; 267: 4854-4858Google Scholar). Recent work by Loo and Clarke (41Loo T.W. Clarke D.M. J. Biol. Chem. 1995; 270: 21839-21844Google Scholar) provided biochemical evidence for an interaction between each NBD and its respective MSD in P-glycoprotein. We speculate that in CFTR, ICL4 and probably other intracellular loops may link the NBDs to the MSDs. In this way the intracellular loops might couple the activity of the NBDs to the gating of the channel. This function for the ICLs could explain their evolutionary conservation in CFTR from different species and in other ABC transporters. There is precedent for such speculation in P-glycoprotein, where mutagenesis of the intracellular loops can alter substrate specificity (42Currier S.J. Kane S.E. Willingham M.C. Cardarelli C.O. Pastan I. Gottesman M.M. J. Biol. Chem. 1992; 267: 25153-25159Google Scholar, 43Loo T.W. Clarke D.M. J. Biol. Chem. 1994; 269: 28683-28689Google Scholar). In addition, in several prokaryotic ABC transporters, where individual domains are encoded by separate genes, it has been suggested that a conserved sequence motif in a hydrophilic cytosolic loop of the membrane-spanning subunit is the site of interaction with the subunit containing the NBD (44Kerppola R.E. Ames G.F. J. Biol. Chem. 1992; 267: 2329-2336Google Scholar, 45Dassa E. Mol. Microbiol. 1993; 7: 39-47Google Scholar). These data also have implications for CF. First, an understanding of how particular CF-causing mutations disrupt CFTR function may prove helpful in the design and development of suitable therapies. For example, processing of several of the ICL4 mutants was not completely disrupted suggesting that some of the mutant protein may traffic to the plasma membrane. In such cases interventions designed to increase the activity of the mutant protein could potentially be of therapeutic benefit. Second, knowledge of how ICL4 mutations disrupt processing could help provide a better understanding of how the more common ΔF508 mutation disrupts processing. Third, these results provide some information about the relationship between genotype and phenotype. There are reports that several of the mutations (for example, F1052V, H1054D, and L1077P) are associated with a milder, pancreatic sufficient phenotype in which pancreatic function is not completely defective (17Mercier B. Lissens W. Novelli G. Kalaydjieva L. DeArce M. Kapranov N. Canki-Klain N. Lenoir G. Chauveau P. Lenaerts C. Rault S. Cashman S. Sanguiolo F. Audrézet M.P. Dallapiccola B. Guillermit H. Bonduelle M. Liebaers I. Quéré I. Verlingue C. Ferec C. Genomics. 1993; 16: 296-297Google Scholar, 20Bozon D. Zielenski J. Rininsland F. Tsui L.-C. Hum. Mutat. 1994; 3: 330-332Google Scholar, 46Férec C. Verlingue C. Guillermit H. Quéré I. Raguénés O. Feigelson J. Audrézet M.P. Mercier B. Hum. Mol. Genet. 1993; 2 (4865t1): 1557-1560Google Scholar). Our data suggest that in those mutants at least some of the protein is correctly processed. Therefore the pancreatic sufficient phenotype could result from residual activity of the mutant protein at the cell surface. However, not all of the data are as readily interpretable. For example, H1085R is misprocessed like ΔF508, yet it is reported to occur in a patient with a pancreatic sufficient phenotype. Conversely, our data with the mutants R1066L, R1066H, and A1067T are similar to that obtained with the “mild” mutants A455E and P574H (10Sheppard D.N. Ostedgaard L.S. Winter M.C. Welsh M.J. EMBO J. 1995; 14: 876-883Google Scholar) in that they retained partial processing and function. Yet those three ICL4 mutants were reported to be associated with a pancreatic insufficient phenotype (15Férec C. Audrézet M.P. Mercier B. Guillermit H. Moullier P. Quéré I. Verlingue C. Nat. Genet. 1992; 1: 188-191Google Scholar, 17Mercier B. Lissens W. Novelli G. Kalaydjieva L. DeArce M. Kapranov N. Canki-Klain N. Lenoir G. Chauveau P. Lenaerts C. Rault S. Cashman S. Sanguiolo F. Audrézet M.P. Dallapiccola B. Guillermit H. Bonduelle M. Liebaers I. Quéré I. Verlingue C. Ferec C. Genomics. 1993; 16: 296-297Google Scholar). In attempting to draw correlations about genotype, mechanism of dysfunction, and clinical phenotype, caution is warranted. Most of the mutations we studied are very rare in patients and therefore it is difficult to be confident of the clinical phenotype. However, further investigation into the relationship between genotype, mechanism of dysfunction, and clinical phenotype should yield new insight into how mutations in CFTR produce disease. We thank Pary Weber, Dan Vermeer, Lisa deBerg, Gina Hill, and Renae Szemkus for excellent technical assistance and our other laboratory colleagues for their comments and discussions." @default.
• W1989544135 created "2016-06-24" @default.
• W1989544135 creator A5005565032 @default.
• W1989544135 creator A5007052039 @default.
• W1989544135 creator A5037321572 @default.
• W1989544135 creator A5063769358 @default.
• W1989544135 date "1996-08-01" @default.
• W1989544135 modified "2023-09-28" @default.
• W1989544135 title "Effect of Cystic Fibrosis-associated Mutations in the Fourth Intracellular Loop of Cystic Fibrosis Transmembrane Conductance Regulator" @default.
• W1989544135 cites W1499612376 @default.
• W1989544135 cites W1528658828 @default.
• W1989544135 cites W1535422451 @default.
• W1989544135 cites W1588246354 @default.
• W1989544135 cites W1590184168 @default.
• W1989544135 cites W1975971473 @default.
• W1989544135 cites W1979215455 @default.
• W1989544135 cites W1980180966 @default.
• W1989544135 cites W1985771789 @default.
• W1989544135 cites W1988106177 @default.
• W1989544135 cites W1993935349 @default.
• W1989544135 cites W2009667219 @default.
• W1989544135 cites W2015655328 @default.
• W1989544135 cites W2016340216 @default.
• W1989544135 cites W2019702541 @default.
• W1989544135 cites W2024715411 @default.
• W1989544135 cites W2025525982 @default.
• W1989544135 cites W2025610536 @default.
• W1989544135 cites W2025901527 @default.
• W1989544135 cites W2036931150 @default.
• W1989544135 cites W2040091117 @default.
• W1989544135 cites W2047958782 @default.
• W1989544135 cites W2050573110 @default.
• W1989544135 cites W2051296698 @default.
• W1989544135 cites W2052588826 @default.
• W1989544135 cites W2058321605 @default.
• W1989544135 cites W2058600907 @default.
• W1989544135 cites W2061592889 @default.
• W1989544135 cites W2064390823 @default.
• W1989544135 cites W2068233575 @default.
• W1989544135 cites W2071258132 @default.
• W1989544135 cites W2075257287 @default.
• W1989544135 cites W2079234445 @default.
• W1989544135 cites W2080423498 @default.
• W1989544135 cites W2082968284 @default.
• W1989544135 cites W2088295492 @default.
• W1989544135 cites W2125428336 @default.
• W1989544135 cites W2156642288 @default.
• W1989544135 cites W2170734806 @default.
• W1989544135 cites W2173634416 @default.
• W1989544135 cites W2332646752 @default.
• W1989544135 cites W310454076 @default.
• W1989544135 cites W92174230 @default.
• W1989544135 doi "https://doi.org/10.1074/jbc.271.35.21279" @default.
• W1989544135 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/8702904" @default.
• W1989544135 hasPublicationYear "1996" @default.
• W1989544135 type Work @default.
• W1989544135 sameAs 1989544135 @default.
• W1989544135 citedByCount "93" @default.
• W1989544135 countsByYear W19895441352012 @default.
• W1989544135 countsByYear W19895441352013 @default.
• W1989544135 countsByYear W19895441352014 @default.
• W1989544135 countsByYear W19895441352015 @default.
• W1989544135 countsByYear W19895441352016 @default.
• W1989544135 countsByYear W19895441352017 @default.
• W1989544135 countsByYear W19895441352018 @default.
• W1989544135 countsByYear W19895441352020 @default.
• W1989544135 countsByYear W19895441352021 @default.
• W1989544135 countsByYear W19895441352022 @default.
• W1989544135 countsByYear W19895441352023 @default.
• W1989544135 crossrefType "journal-article" @default.
• W1989544135 hasAuthorship W1989544135A5005565032 @default.
• W1989544135 hasAuthorship W1989544135A5007052039 @default.
• W1989544135 hasAuthorship W1989544135A5037321572 @default.
• W1989544135 hasAuthorship W1989544135A5063769358 @default.
• W1989544135 hasBestOaLocation W19895441351 @default.
• W1989544135 hasConcept C104317684 @default.
• W1989544135 hasConcept C114614502 @default.
• W1989544135 hasConcept C121332964 @default.
• W1989544135 hasConcept C121932024 @default.
• W1989544135 hasConcept C12554922 @default.
• W1989544135 hasConcept C126322002 @default.
• W1989544135 hasConcept C170493617 @default.
• W1989544135 hasConcept C184670325 @default.
• W1989544135 hasConcept C185592680 @default.
• W1989544135 hasConcept C24530287 @default.
• W1989544135 hasConcept C26873012 @default.
• W1989544135 hasConcept C2776938444 @default.
• W1989544135 hasConcept C2778428886 @default.
• W1989544135 hasConcept C2780559512 @default.
• W1989544135 hasConcept C33923547 @default.
• W1989544135 hasConcept C54355233 @default.
• W1989544135 hasConcept C6929976 @default.
• W1989544135 hasConcept C71924100 @default.
• W1989544135 hasConcept C79879829 @default.
• W1989544135 hasConcept C86803240 @default.
• W1989544135 hasConcept C95444343 @default.
• W1989544135 hasConceptScore W1989544135C104317684 @default.
• W1989544135 hasConceptScore W1989544135C114614502 @default.

• next